

Common Pulmonary Diseases in Dogs

Douglas Palma, DVM, DACVIM (SAIM)
The Animal Medical Center
 New York, New York



YOU HAVE ASKED ...

What should I know about common canine pulmonary diseases?

THE EXPERT SAYS ...

Pulmonary disease is a common cause of respiratory signs in dogs. A thorough history and examination help localize the pulmonary parenchyma rather than other parts of the respiratory system. Signalment, clinical onset and progression, geographic location, and additional organ involvement can help prioritize differential diagnoses.

Patients with pulmonary disease may exhibit coughing, increased respiratory rate, dyspnea, and/or exercise intoler-

ance. Depending on cause and nonrespiratory involvement, nonspecific clinical signs (eg, lethargy, inappetence, weight loss) may be present. Many patients may have a mixed pattern of breathing characterized by increased inspiratory and expiratory effort, as the disease processes may involve concurrent airway obstruction and altered lung compliance. Therefore, a pure restrictive (decreased tidal volume, increased respiratory rate) or obstructive (increased expiratory effort) pattern of breathing is often not observed.

The following are pulmonary diseases frequently encountered in dogs.

Pneumonia

Bacterial Pneumonia

Pneumonia may be community-acquired (ie, characterized by bronchopneumonia

CDV = canine distemper virus
 CIV = canine influenza virus
 EB = eosinophilic bronchopneumopathy
 PCR = polymerase chain reaction
 RT-PCR = reverse transcription polymerase chain reaction

in a dog with a history of being housed in the community) or secondary to altered pulmonary defenses, aspiration, or hematogenous infection.

Community-acquired pneumonia is most common in young dogs and in dogs with recent exposure to kennels or shelters.¹ Exposure to other dogs makes *Bordetella bronchiseptica* most common, but other opportunistic pathogens may be involved.¹ *Streptococcus zooepidemicus*, another emerging bacterial pathogen, is associated with development of hemorrhagic pneumonia.²


Aspiration pneumonia is more common in older patients. Clinical history is important to help identify potential underlying causes. The most commonly reported causes of aspiration pneumonia in dogs include esophageal disease, vomiting, neurologic disorders, laryngeal disease, and postanesthetic aspiration.³ Opportunistic infections complicate the initial aspiration event. A mixed population of bacteria with an anaerobic population is common. Aspiration pneumonia is typically characterized by a distribution to the most dependent lung lobe (ie, right middle). However, distribution to any lung or multiple lungs is possible.⁴ Although respiratory signs may be present, many older patients are clinically silent; pneumonia must be considered in dogs with nonspecific signs of lethargy, inappetence, and/or fatigue.

Dogs with bacterial pneumonia are typically presented with acute-onset coughing, lethargy, inappetence, and/or respiratory distress. An inflammatory leukogram and pyrexia, although common, are not always present. Radiographs may reveal an interstitial-to-alveolar pattern with a cranioventral distribution (*Figure 1*). Atypical distributions can also occur.⁵

Culture-directed therapy is ideal; however, empiric treatment with knowledge of common organisms is reasonable.⁶ Multidrug-resistant organisms are more common following recent antibiotic exposure.^{7,8}

Viral Pneumonia

Viral pneumonia is generally associated with canine distemper virus (CDV) or canine influenza virus (CIV). Emerging viral pathogens (eg, canine pantropic coronavirus, canine pneumovirus) have



▲ **FIGURE 1** (A) Bronchopneumonia. Cranioventral distribution of alveolar disease with air bronchograms. (B) A patchy distribution can be observed on the lateral projection. The changes overlying the heart may be missed in subtle cases.

recently been described.⁹ Canine herpesvirus can, albeit rarely, induce interstitial pneumonia.^{10,11}


CDV should be suspected in poorly vaccinated dogs with multiorgan involvement. Dogs with CDV may have exhibited only respiratory signs before developing characteristic nonrespiratory signs.¹² Radiographs may reveal a diffuse interstitial pattern (*Figure 2*). Diagnosis is supported by compatible clinical signs and complementary diagnostic testing (ie, real-time reverse transcription polymerase chain reaction [RT-PCR], serology, CSF pleocytosis). Conjunctival scraping and tissue-based immunohistochemistry may confirm diagnosis.

CIV may involve the pulmonary parenchyma and is often complicated by opportunistic bacteria. Patients typically are presented with lethargy, anorexia, nasal discharge, and coughing. PCR of the nasal cavity or oropharynx within 3 to 5 days of infection may confirm organism presence. Patients with clinical signs lasting longer than 5 days may require serologic testing.¹³


Fungal Pneumonia

The incidence of fungal disease varies widely by geographic region. Dogs with fungal pneumonia are generally young and exhibit signs of generalized illness (eg, lethargy, weight loss, pyrexia, decreased appetite). Many patients with pulmonary involvement do not show respiratory signs; coughing and respiratory distress are most common among those that do.¹⁴⁻¹⁶ Additional organ systems (eg, dermatologic, GI, ocular, musculoskeletal) may be affected.¹⁷

Blood testing is somewhat nonspecific. Common abnormalities include hypoal-



▲ **FIGURE 2** CDV pneumonia with a diffuse interstitial pattern confirmed by multisystemic signs, urine RT-PCR, and necropsy



▲ **FIGURE 3** Eosinophilic bronchopneumopathy. Note the heavy, patchy bronchointerstitial pattern.

buminemia, hyperglobulinemia, nonregenerative anemia, and monocytosis; hypercalcemia and eosinophilia are less common. An inflammatory leukogram may be observed. Radiographs often show a miliary pattern and may show hilar lymphadenopathy. A combination of serologic and antigen testing may support diagnosis. Cytology or tissue histopathology may identify the organism.¹⁸⁻²¹

Eosinophilic Bronchopneumopathy

Eosinophilic bronchopneumopathy (EB) is an idiopathic inflammatory

hypersensitivity disorder associated with acute onset coughing, gagging, retching, and/or respiratory distress. Radiographs may reveal a diffuse bronchointerstitial pattern or alveolar disease (**Figure 3**, previous page). Patients with EB have airway cytology supportive of eosinophilic inflammation and are negative for parasitic testing.


EB's acute nature, occurrence in young animals, and radiographic findings may mimic pneumonia. EB should be suspected in patients that fail treat-

ment for pneumonia, have peripheral eosinophilia, or have uncharacteristically severe diffuse bronchointerstitial patterns; further diagnostic investigation is indicated to confirm eosinophilic inflammation and rule out other causes. Treatment with corticosteroids is often successful; however, relapse can occur after dose tapering.²²

Pulmonary Edema

Noncardiogenic and cardiogenic edema are common causes of pulmonary parenchymal changes in dogs.

EB = eosinophilic bronchopneumopathy



▲ **FIGURE 4** (A & B) Congestive heart failure. Note the left-sided cardiomegaly, pulmonary venous congestion, and interstitial pulmonary pattern. Edema is not exclusively perihilar. (C & D) Noncardiogenic edema with bilateral, symmetrical caudodorsal distribution without venous congestion or cardiomegaly

Cardiogenic edema is caused by increased hydrostatic pressure and is readily diagnosed by thoracic radiographic documentation of left-sided cardiomegaly, pulmonary venous congestion, and a patchy interstitial or alveolar pattern (frequently perihilar). Echocardiographic evaluation may support diagnosis.²³ Natriuretic peptides may provide additional insight in differentiation between congestive heart failure and other causes of respiratory distress (**Figure 4**). Plasma B-type natriuretic peptide has been shown to have discriminatory value in dogs; however, some degree of overlap exists between groups.²⁴


Noncardiogenic edema is a low-pressure edema characterized by increased blood vessel permeability. Seizures, electrocution, strangulation or upper airway obstruction, local pulmonary disease, and systemic inflammatory response syndrome (ie, acute respiratory distress syndrome) are the most commonly reported causes.^{25,26}

Thorough clinical history and physical examination are necessary to identify potential underlying causes. Careful auscultation of the upper airways is important. Radiographs often reveal bilateral, caudodorsal interstitial, and/or alveolar disease. Radiographic progression can occur for as long as 48 hours.²⁷

Lungworms

Lungworms may cause bronchitis and pneumonia. Chronic coughing is the most common clinical sign. Acute-onset exercise intolerance and/or respiratory distress may also be seen.

Radiographic evaluation can vary from a diffuse bronchointerstitial pattern to



▲ **FIGURE 5** *Crenosoma vulpis* (ie, lungworm). Note the patchy, unstructured interstitial densities. Larvae were recovered on bronchoscopy.

patchy interstitial or alveolar infiltrates (**Figure 5**).²⁸ Bullae may occasionally be appreciated in association with some infections (eg, *Paragonimus kellicotti*).²⁹⁻³¹

Peripheral eosinophilia is not always present with infection. Eosinophilic inflammation on airway cytology supports diagnosis. Identification of larvae or oocysts via fecal testing (eg, Baermann technique, fecal centrifugation) or airway sampling confirms diagnosis.³² False-negative results can occur; any patient with eosinophilic bronchitis should be treated empirically. An extended course of fenbendazole (ie, 2 weeks) is generally recommended to treat most pulmonary worms.

Lung Lobe Torsion

Spontaneous lung lobe torsion occurs in dogs (most commonly pugs and Afghan hounds³³), can occur in any lung lobe, and may be secondary to pleural effusion or thoracic surgery. The right middle lung lobe is overrepresented in deep-chested dogs; the left cranial lung lobe is overrepresented in pugs.^{33,34}

Nonspecific illness and respiratory signs may be appreciated. Leukocytosis, left shift, and pyrexia may be present.³⁴ Radiographs often reveal an alveolar pattern, trapped gas (vesiculated), and/or pleural effusion. Bronchial malpositioning is uncommon (**Figure 6**).³⁵ Confirmation via ultrasonography, bronchoscopy, and/or CT is recommended.^{36,37} Pleural fluid varies widely in gross and cytologic appearance. Although nonspecific, the presence of pleural fluid, alveolar disease, and acute respiratory signs is suggestive. Immediate lung lobectomy is warranted.

Pulmonary Neoplasia

Radiographs usually reveal structured interstitial densities within pulmonary parenchyma.³⁸ These lesions may represent primary or metastatic lesions. Clinical signs are typically absent, although coughing is most common. Acute respiratory signs may occur secondary to generation of pleural effusion or bleeding from a lesion (ie, hemangiosarcoma metastasis). Depending on the extent of disease, anorexia, lethargy, and weight loss may be appreciated.³⁹

Pulmonary neoplasia may, on occasion, have a more diffuse nature. This is common with pulmonary lymphoma⁴⁰ and is sometimes seen with carcinoma (author experience). Pulmonary lymphoma can have a rapid clinical course and mimic acute disorders. A diffuse, unstructured interstitial pattern is typically appreciated. Additionally, bronchointerstitial, alveolar, and nodular patterns may be observed (**Figure 7**).⁴⁰



Diagnosis of pulmonary lymphoma requires airway cytology, pulmonary fine-needle aspiration, and/or confirmation on nonpulmonary samples.⁴¹

Carcinoma frequently causes anorexia and weight loss and should be considered in older patients with refractory pneumonia.⁴²

Pulmonary Embolism

Pulmonary embolism (PE) should be suspected in dogs with acute respiratory signs, hypoxemia, and minimal radiographic changes. More common disorders should be ruled out. Radiographic

PAH = pulmonary arterial hypertension
PE = pulmonary embolism




▲ **FIGURE 6 (A & B)** Lung lobe torsion. Note classic vesicular pattern associated with gas trapping and pleural effusion. Bronchial attenuation or displacement is subtle and often absent.

findings vary from normal to patchy/wedge-shaped alveolar/interstitial infiltrates. Pulmonary oligemia may be appreciated in some patients (**Figure 8**, next page).

Diagnostics should focus on documenting a predisposing hypercoagulable state and attempting to confirm thrombosis. D-dimers, contrast angiography, echocardiography, nuclear medicine, and thoracic CT may indicate PE.⁴³⁻⁴⁵ Microvascular thrombosis may only be documented on necropsy. However, no test can reliably rule out PE; therefore, treatment must be considered for patients in which the condition is suspected. Optimal management has not been described; however, anticoagulant therapy is standard in human patients. Thrombolytic therapy is standard in humans with massive pulmonary thromboembolism (hemodynamically unstable). Recently, subpopulations of submassive pulmonary thromboembolism (hemodynamically stable) have benefitted from thrombolytic therapy.⁴⁶ Optimal thrombolytic protocols have not been designed for dogs or cats.

Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) may be a primary vascular disorder or secondary to cardiac disease, pulmonary disease, or pulmonary embolism. The most commonly cited causes of PAH in dogs include chronic acquired valvular disease, pulmonary disease, pulmonary overcirculation, and heartworm disease.⁴⁷⁻⁵² Primary pulmonary hypertension has been described in dogs in association with a pulmonary arteriopathy⁵³ and a primary pulmonary veno-occlusive condition.⁵⁴ Patients may be subclinical or may show signs of hypoxia (eg, weakness, fatigue, shortness of



▲ **FIGURE 7** (A) Pulmonary lymphoma with a diffuse, patchy bronchointerstitial pattern confirmed on bronchoalveolar lavage and peripheral lymph node aspiration. (B) Pulmonary carcinoma with a diffuse, severe bronchointerstitial pattern confirmed on bronchoalveolar lavage and postmortem examination. Note: Pulmonary and hilar lymphadenopathy are not always present.

breath, exercise intolerance, collapse, syncope, right-sided congestive heart failure [rare]). Coughing is common and is often associated with secondary causes of PAH.⁵² Radiographic features and physical examination results generally reflect the underlying disease process; rarely, pulmonary edema may be observed.⁵⁵ Investigation may be warranted in at-risk patients (ie, patients with diffuse crackles, West Highland terriers with pulmonary fibrosis).

Documentation of PAH can be performed indirectly with echocardiography.^{56,57} Direct pulmonary arterial measurement is rarely performed. PAH often contributes to signs with any chronic cardiopulmonary disease; thus, screening is recommended. Phosphodiesterase type V inhibitors (eg, sildenafil,^{49,50,58} tadalafil⁵⁹), pimobendan,⁶⁰ and imatinib⁶¹ may be considered, depending on cause.



▲ **FIGURE 8** Pulmonary embolism confirmed on necropsy. Note the right caudal lung field oligemia, which signifies vascular occlusion.



▲ **FIGURE 9** Idiopathic pulmonary fibrosis with a diffuse bronchointerstitial pattern. Idiopathic pulmonary fibrosis was confirmed on lung biopsy.

PAH = pulmonary arterial hypertension

Interstitial Lung Diseases

Interstitial lung diseases are an uncommon cause of respiratory disease in general. The most common interstitial lung disease is idiopathic pulmonary fibrosis, which occurs most commonly in West Highland terriers.⁶² Because of the interstitial location of interstitial lung diseases, histopathology is required for definitive diagnosis.⁶³ Common signs include exercise intolerance, labored breathing, syncope, and weakness.⁶⁴ Coughing is typically not present. Examination may reveal crackles, fatigue, cyanosis, and a restrictive breathing pattern.

Radiographs may reveal a diffuse, unstructured interstitial pattern (**Figure 9**). Subtle changes in interstitial opacity may go unnoticed despite severe histologic disease.⁶²

Thoracic CT may provide strong support with a characteristic diffuse “ground glass” appearance.⁶⁵ This remains non-specific, however, and may be caused by other conditions. Additional supportive diagnostics may include bronchoalveolar lavage biomarkers (eg, endothelin-1)⁶⁶ as well as echocardiography to document secondary pulmonary hypertension.

Additional Disorders

Other pulmonary conditions in dogs include atypical infections (eg, *Mycobacterium* spp, protozoal),^{67,68} traumatic injuries (eg, pulmonary contusions, near-drowning), and inhaled irritants (eg, pneumonitis, smoke). It is important to note that the lungs may represent a manifestation of systemic disease (eg, leptospirosis, acute respiratory distress syndrome, anaphylaxis, transfusion-related acute lung injury). ■

See page 105 for references.

References

- Radhakrishnan A, Drobatz KJ, Culp WT, King LG. Community-acquired infectious pneumonia in puppies: 65 cases (1993-2002). *J Am Vet Med Assoc.* 2007;230(10):1493-1497.
- Priestnall S, Erles K. *Streptococcus zooepidemicus*: an emerging canine pathogen. *Vet J.* 2011;188(2):142-148.
- Kogen DA, Johnson LR, Sturges BK, Jandrey KE, Pollard RE. Etiology and clinical outcome in dogs with aspiration pneumonia: 88 cases (2004-2006). *J Am Vet Med Assoc.* 2008;233(11):1748-1755.
- Kogan DA, Johnson LR, Jandrey KE, Pollard RE. Clinical, clinicopathologic, and radiographic findings in dogs with aspiration pneumonia: 88 cases (2004-2006). *J Am Vet Med Assoc.* 2008;233(11):1742-1747.
- Jameson PH, King LA, Lappin MR, Jones RL. Comparison of clinical signs, diagnostic findings, organisms isolated, and clinical outcome in dogs with bacterial pneumonia: 93 cases (1986-1991). *J Am Vet Med Assoc.* 1995;206(2):206-209.
- Proulx A, Hume DZ, Drobatz KJ, Reineke EL. In vitro bacterial isolate susceptibility to empirically selected antimicrobials in 111 dogs with bacterial pneumonia. *J Vet Emerg Crit Care.* 2014;24(2):194-200.
- Angus JC, Jang SS, Hirsh DC. Microbiological study of transtracheal aspirates from dogs with suspected lower respiratory tract disease: 264 cases (1989-1995). *J Am Vet Med Assoc.* 1997;210(1):55-58.
- Proulx A, Hume D, Drobatz KJ, Reineke EL. In vitro bacterial isolate susceptibility to empirically selected antimicrobials in 111 dogs with bacterial pneumonia. *J Vet Emerg Crit Care (San Antonio).* 2014;24(2):194-200.
- Priestnall SL, Mitchell JA, Walker CA, Erles K, Brownlie J. New and emerging pathogens in canine infectious respiratory disease. *Vet Pathol.* 2014;51(2):492-504.
- Larsen RW, Kiuppel M, Agerholm JS. Prevalence of canine herpesvirus-1 infection in stillborn and dead neonatal puppies in Denmark. *Acta Vet Scand.* 2015;52:1.
- Kumar S, Driskell EA, Cooley AJ, et al. Fatal canine herpesvirus 1 respiratory infections in 4 clinically healthy adult dogs. *Vet Pathol.* 2015;52(4):681-687.
- Pandher K, Podell B, Gould DH, Johnson BJ, Thompson S. Interstitial pneumonia in neonatal canine pups with evidence of canine distemper virus infection. *J Vet Diagn Invest.* 2006;18(2):201-214.
- Dubovi EJ, Njaa BL. Canine Influenza. *Vet Clin North Am Small Anim Pract.* 2008;38(4):827-835.
- Johnson LR, Herrgesell EJ, Davidson AP, Pappagianis D. Clinical, clinicopathologic, and radiographic findings in dogs with coccidioidomycosis: 24 cases (1995-2000). *J Am Vet Med Assoc.* 2003;222(4):461-466.
- Clinkenbeard KD, Cowell RL, Tyler RD. Disseminated histoplasmosis in dogs: 12 cases (1981-1986). *J Am Vet Med Assoc.* 1988;193(11):1443-1447.
- Arceneaux KA, Taboada J, Hosgood G. Blastomycosis in dogs: 115 cases (1980-1995). *J Am Vet Med Assoc.* 1998;213(5):658-664.
- Roudebush P. Mycotic pneumonias. *Vet Clin North Am Small Anim Pract.* 1985;15(5):949-969.
- Bromel C, Sykes JE. Epidemiology, diagnosis, and treatment of blastomycosis in dogs and cats. *Clin Tech Small Anim Pract.* 2005;20(4):233-239.
- Arceneaux KA, Taboada J, Hosgood G. Blastomycosis in dogs: 115 cases (1980-1995). *J Am Vet Med Assoc.* 1998;213(5):658-664.
- Spector D, Wheat LJ, Beamis D, et al. Antigen testing for the diagnosis of blastomycosis. *J Vet Intern Med.* 2006;20(3):711-712.
- Hage CA, Knox KS, Davis TE, Wheat LJ. Antigen detection in bronchoalveolar lavage fluid for diagnosis of fungal pneumonia. *Curr Opin Pulm Med.* 2011;17(3):167-171.
- Clercx C, Peeters D, Snaps F, et al. Eosinophilic bronchopneumopathy in dogs. *J Vet Intern Med.* 2000;14(3):282-291.
- Diana A, Guglielmini C, Pivetta M, et al. Radiographic features of cardiogenic pulmonary edema in dogs with mitral regurgitation: 61 cases (1998-2007). *J Am Vet Med Assoc.* 2009;235(9):1058-1063.
- Smith KF, Quinn RL, Rahilly LJ. Biomarkers for differentiation of causes of respiratory distress in dogs and cats: part 1—Cardiac diseases and pulmonary hypertension. *J Vet Emerg Crit Care (San Antonio).* 2015;25(3):311-329.
- Drobatz KJ, Saunders HM, Pugh CR, Hendricks JC. Noncardiogenic pulmonary edema in dogs and cats: 26 cases (1987-1993). *J Am Vet Med Assoc.* 1995;206(11):1732-1736.
- Hughes D. Pulmonary Edema. In: King LG, ed. *Textbook of Respiratory Diseases in Dogs and Cats.* St. Louis, MO: Elsevier; 2004;487-497.
- Bachmann M, Waldrop JE. Noncardiogenic edema. *Compend Contin Educ Vet.* 2012;34(11):E1.
- Sherding RG. Parasites of the lung. In: King LG, ed. *Textbook of Respiratory Diseases in Dogs and Cats.* St. Louis, MO: Elsevier; 2004;548-559.
- Pechman RD. The radiographic features of pulmonary paragonimiasis in the dog and cat. *J Am Vet Radiol Soc.* 1976;17(5):182-191.
- Pechman RD Jr. Pulmonary paragonimiasis in dogs and cats: a review. *J Small Anim Pract.* 1980;21(2):87-95.
- Herman LH, Helland DR. Paragonimiasis in a cat. *J Am Vet Med Assoc.* 1966;149(6):753-757.
- Bihl T, Conboy GA. Lungworm (*Crenosoma vulpis*) infection in dogs on Prince Edward Island. *Can Vet J.* 1999;40(8):555-559.
- Murphy KA, Brisson BA. Evaluation of a lung lobe torsion in Pugs: 7 cases (1991-2004). *J Am Vet Med Assoc.* 2006;228(1):86-90.
- Neath PJ, Brockman DJ, King LG. Lung lobe torsion in dogs: 22 cases (1981-1999). *J Am Vet Med Assoc.* 2000;217(7):1041-1044.
- d'Anjou MA, Tidwell AS, Hecht S. Radiographic diagnosis of lung lobe torsion. *Vet Radiol Ultrasound.* 2005;46(6):478-484.
- Caivano D, Biretoni F, Bufalari A, et al. Contrast-enhanced ultrasound findings in three dogs with lung lobe torsion. *J Vet Med Sci.* 2015;78(3):427-430.
- Seiler G, Schwarz T, Vignoli M, Rodriguez D. Computed tomography features of lung lobe torsion. *Vet Radiol Ultrasound.* 2008;49(6):504-508.
- Barrett LE, Pollard RE, Zwingenberger A, Zierenberg-Ripoll A, Skorupski KA. Radiographic characterization of primary lung tumors in 74 dogs. *Vet Radiol Ultrasound.* 2014;55(5):480-487.
- Baez JL, Sorenmo U. Pulmonary and bronchial neoplasia. *Textbook of Respiratory Diseases in Dogs and Cats.* St. Louis, MO: Elsevier; 2004;508-516.
- Geyer NE, Reichle JK, Valdés-Martínez A, et al. Radiographic appearance of confirmed pulmonary

Continues on page 108

lymphoma in cats and dogs. *Vet Radiol Ultrasound*. 2010;51(4):386-390.

41. Hawkins EC, Morrison WB, DeNicola DB, Blevins WE. Cytologic analysis of bronchoalveolar lavage fluid from 47 dogs with multicentric malignant lymphoma. *J Am Vet Med Assoc*. 1993;203(10):1418-1425.
42. Bertazzolo W, Zuliani D, Pogliani E, Caniatti M, Bussadori C. Diffuse bronchiolo-alveolar carcinoma in a dog. *J Small Anim Pract*. 2002;43(6):265-268.
43. LaRue MJ, Murtaugh RJ. Pulmonary thromboembolism in dogs: 47 cases (1986-1987). *J Am Vet Med Assoc*. 1990;197(10):1368-1372.
44. Goggs R, Benigni L, Fuentes VL, Chan DL. Pulmonary embolism. *J Vet Emerg Crit Care (San Antonio)*. 2009;19(1):30-52.
45. Johnson LR, Lappin MR, Baker DC. Pulmonary thromboembolism in 29 dogs: 1985-1995. *J Vet Intern Med*. 1999;13(4):338-345.
46. Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W. Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta-analysis. *J Thromb Haemost*. 2014;12(7):1086-1095.
47. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler derived evidence of pulmonary hypertension: 1992-1996. *J Vet Intern Med*. 1999;13(5):440-447
48. Pyle RL, Abbott J, MacLean H. Pulmonary hypertension and cardiovascular sequelae in 54 dogs. *Int J Appl Res Vet Med*. 2004;2(2):99.
49. Bach JF, Rozanski EA, MacGregor J, et al. Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. *J Vet Intern Med*. 2006;20(5):1132-1135.
50. Kellum HB, Stepien RL. Sildenafil citrate therapy in 22 dogs with pulmonary hypertension. *J Vet Intern Med*. 2007;21(6):1258-1264.
51. Serres F, Chetboul V, Gouni V, et al. Diagnostic value of echo-Doppler and tissue Doppler imaging in dogs with pulmonary arterial hypertension. *J Vet Intern Med*. 2007;21(6):1280-1289.
52. Kelliham HB, Stepien, RL. Pulmonary hypertension in dogs: diagnosis and therapy. *Vet Clin North Am Small Anim Pract*. 2010;40(4):623-640.
53. Zabka TS, Campbell FE, Wilson DW. Pulmonary arteriopathy and idiopathic pulmonary arterial hypertension in six dogs. *Vet Pathol*. 2006;43(4):510-522.
54. Williams K, Andrie K, Cartoceti A, et al. Pulmonary



IN CLINIC ANTIBODY TITER TEST



MEASURES ANTIBODY TITER TO:

RESULTS IN JUST 21 MINUTES WHILE THE PATIENT WAITS!


Feline panleukopenia kits now available!
VACCICHECK.COM



PARVOVIRUS

DISTEMPER

INFECTIOUS HEPATITIS



NexGard® (afoxolaner) Chewables

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Description:

NexGard® (afoxolaner) is available in four sizes of beef-flavored, soft chewables for oral administration to dogs and puppies according to their weight. Each chewable is formulated to provide a minimum afoxolaner dosage of 1.14 mg/lb (2.5 mg/kg). Afoxolaner has the chemical composition 1-Naphthalenecarboxamide, 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl].

Indications:

NexGard kills adult fleas and is indicated for the treatment and prevention of flea infestations (*Ctenocephalides felis*), and the treatment and control of Black-legged tick (*Ixodes scapularis*), American Dog tick (*Dermacentor variabilis*), Lone Star tick (*Amblyomma americanum*), and Brown dog tick (*Rhipicephalus sanguineus*) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for one month.

Dosage and Administration:

NexGard is given orally once a month, at the minimum dosage of 1.14 mg/lb (2.5 mg/kg).

Dosing Schedule:

Body Weight	Afoxolaner Per Chewable (mg)	Chewables Administered
4.0 to 10.0 lbs.	11.3	One
10.1 to 24.0 lbs.	28.3	One
24.1 to 60.0 lbs.	68	One
60.1 to 121.0 lbs.	136	One
Over 121.0 lbs.	Administer the appropriate combination of chewables	

NexGard can be administered with or without food. Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes to ensure that part of the dose is not lost or refused. If it is suspected that any of the dose has been lost or if vomiting occurs within two hours of administration, redose with another full dose. If a dose is missed, administer NexGard and resume a monthly dosing schedule.

Flea Treatment and Prevention:

Treatment with NexGard may begin at any time of the year. In areas where fleas are common year-round, monthly treatment with NexGard should continue the entire year without interruption.

To minimize the likelihood of flea reinfestation, it is important to treat all animals within a household with an approved flea control product.

Tick Treatment and Control:

Treatment with NexGard may begin at any time of the year (see **Effectiveness**).

Contraindications:

There are no known contraindications for the use of NexGard.

Warnings:

Not for use in humans. Keep this and all drugs out of the reach of children. In case of accidental ingestion, contact a physician immediately.

Precautions:

The safe use of NexGard in breeding, pregnant or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures (see **Adverse Reactions**).

Adverse Reactions:

In a well-controlled US field study, which included a total of 333 households and 615 treated dogs (415 administered afoxolaner; 200 administered active control), no serious adverse reactions were observed with NexGard.

Over the 90-day study period, all observations of potential adverse reactions were recorded. The most frequent reactions reported at an incidence of > 1% within any of the three months of observations are presented in the following table. The most frequently reported adverse reaction was vomiting. The occurrence of vomiting was generally self-limiting and of short duration and tended to decrease with subsequent doses in both groups. Five treated dogs experienced anorexia during the study, and two of those dogs experienced anorexia with the first dose but not subsequent doses.

Table 1: Dogs With Adverse Reactions.

	Treatment Group			
	Afoxolaner		Oral active control	
	N ¹	% (n=415)	N ²	% (n=200)
Vomiting (with and without blood)	17	4.1	25	12.5
Dry/Flaky Skin	13	3.1	2	1.0
Diarrhea (with and without blood)	13	3.1	7	3.5
Lethargy	7	1.7	4	2.0
Anorexia	5	1.2	9	4.5

¹Number of dogs in the afoxolaner treatment group with the identified abnormality.

²Number of dogs in the control group with the identified abnormality.

In the US field study, one dog with a history of seizures experienced a seizure on the same day after receiving the first dose and on the same day after receiving the second dose of NexGard. This dog experienced a third seizure one week after receiving the third dose. The dog remained enrolled and completed the study. Another dog with a history of seizures had a seizure 15 days after the third dose of NexGard. The dog remained enrolled and completed the study. A third dog with a history of seizures received NexGard and experienced no seizures throughout the study.

To report suspected adverse events, for technical assistance or to obtain a copy of the MSDS, contact Merial at 1-888-637-4251 or www.merial.com/NexGard. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

Mode of Action:

Afoxolaner is a member of the isoxazoline family, shown to bind at a binding site to inhibit insect and acarine ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. Prolonged afoxolaner-induced hyperexcitation results in uncontrolled activity of the central nervous system and death of insects and acarines. The selective toxicity of afoxolaner between insects and acarines and mammals may be inferred by the differential sensitivity of the insects and acarines' GABA receptors versus mammalian GABA receptors.

Effectiveness:

In a well-controlled laboratory study, NexGard began to kill fleas four hours after initial administration and demonstrated >99% effectiveness at eight hours. In a separate well-controlled laboratory study, NexGard demonstrated 100% effectiveness against adult fleas 24 hours post-infestation for 35 days, and was ≥ 93% effective at 12 hours post-infestation through Day 21, and on Day 35. On Day 28, NexGard was 81.1% effective 12 hours post-infestation. Dogs in both the treated and control groups that were infested with fleas on Day -1 generated flea eggs at 12- and 24-hours post-treatment (0-11 eggs and 1-17 eggs in the NexGard treated dogs, and 4-90 eggs and 0-118 eggs in the control dogs, at 12- and 24-hours, respectively). At subsequent evaluations post-infestation, fleas from dogs in the treated group were essentially unable to produce any eggs (0-1 eggs) while fleas from dogs in the control group continued to produce eggs (1-141 eggs).

In a 90-day US field study conducted in households with existing flea infestations of varying severity, the effectiveness of NexGard against fleas on the Day 30, 60 and 90 visits compared with baseline was 38.0%, 99.7%, and 99.9%, respectively.

Collectively, the data from the three studies (two laboratory and one field) demonstrate that NexGard kills fleas before they can lay eggs, thus preventing subsequent flea infestations after the start of treatment of existing flea infestations.

In well-controlled laboratory studies, NexGard demonstrated >97% effectiveness against *Dermacentor variabilis*, >94% effectiveness against *Ixodes scapularis*, and >93% effectiveness against *Rhipicephalus sanguineus*, 48 hours post-infestation for 30 days. At 72 hours post-infestation, NexGard demonstrated >97% effectiveness against *Amblyomma americanum* for 30 days.

Animal Safety:

In a margin of safety study, NexGard was administered orally to 8 to 9-week-old Beagle puppies at 1, 3, and 5 times the maximum exposure dose (6.3 mg/kg) for three treatments every 28 days, followed by three treatments every 14 days, for a total of six treatments. Dogs in the control group were sham-dosed. There were no clinically-relevant effects related to treatment on physical examination, body weight, food consumption, clinical pathology (hematology, clinical chemistries, or coagulation tests), gross pathology, histopathology or organ weights. Vomiting occurred throughout the study, with a similar incidence in the treated and control groups, including one dog in the 5x group that vomited four hours after treatment.

In a well-controlled field study, NexGard was used concomitantly with other medications, such as vaccines, anthelmintics, antibiotics (including topicals), steroids, NSAIDs, anesthetics, and antihistamines. No adverse reactions were observed from the concomitant use of NexGard with other medications.

Storage Information:

Store at or below 30°C (86°F) with excursions permitted up to 40°C (104°F).

How Supplied:

NexGard is available in four sizes of beef-flavored soft chewables: 11.3, 28.3, 68 or 136 mg afoxolaner. Each chewable size is available in color-coded packages of 1, 3 or 6 beef-flavored chewables.

NADA 141-406, Approved by FDA

Marketed by: Frontline Vet Labs™, a Division of Merial, Inc.

Duluth, GA 30096-4640 USA

Made in Brazil

©NexGard is a registered trademark, and ™FRONTLINE VET LABS

is a trademark, of Merial. ©2015 Merial. All rights reserved.

1050-4433-03

Rev. 1/2015



veno-occlusive disease: a newly recognized cause of severe pulmonary hypertension in dogs. *Vet Pathol.* 2016;53(4):813-822.

55. Kelliham HB, Waller KR, Pinkos A, Steinberg H, Bates ML. Acute resolution of pulmonary alveolar infiltrates in 10 dogs with pulmonary hypertension treated with sildenafil citrate: 2005-2014. *J Vet Cardiol.* 2015;17(3):182-191.
56. Johnson LR. Diagnosis of pulmonary hypertension. *Clin Tech Small Anim Pract.* 1999;14(4):231-236.
57. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. *J Vet Intern Med.* 1999;13(5):440-447.
58. Brown AJ, Davison E, Sleeper MM. Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs. *J Vet Intern Med.* 2010;24(4):850-854.
59. Hori Y, Kondo C, Matsui M, et al. Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension. *Vet J.* 2014;202(2):334-339
60. Atkinson KJ, Fine DM, Thombs LA, et al. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. *J Vet Intern Med.* 2009;23(6):1190-1196.
61. Arita S, Arita N, Hikasa Y. Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs. *Can Vet J.* 2013;54(3):255-261.
62. Heikkila-Laurila HP, Rajamaki MM. Idiopathic pulmonary fibrosis in West Highland white terriers. *Vet Clin North Am Small Anim Pract.* 2014;44(1):129-142.
63. Norris CR, Griffey SM, Walsh, P. Use of keyhole lung biopsy for diagnosis of interstitial lung diseases in dogs and cats: 13 cases (1998-2001). *J Am Vet Med Assoc.* 2002; 221(10):1453-1459.
64. Reiner CR, Cohn LA. Interstitial Lung Diseases. *Vet Clin North Am Small Anim Pract.* 2007;33(5):937-947.
65. Johnson S, Corcoran BM, Wotton PR, Schwarz T, Sullivan M. Thoracic high-resolution computed tomographic findings in dogs with canine idiopathic pulmonary fibrosis. *J Small Anim Pract.* 2005;46(8):381-388.
66. Krafft E, Heikkila HP, Jespers P, et al. Serum and bronchoalveolar lavage fluid endothelin-1 concentrations as diagnostic biomarkers of canine idiopathic pulmonary fibrosis. *J Vet Intern Med.* 2011;25(5):990-996.
67. Martinho AP, Franco MM, Ribeiro MG, et al. Disseminated *Mycobacterium tuberculosis* infection in a dog. *Am J Trop Med Hyg.* 2013;88(3):596-600.
68. Dubey JP, Lindsay DS, Lappin MR. Toxoplasmosis and other intestinal coccidial infections in cats and dogs. *Vet Clin North Am Small Anim Pract.* 2009;39(6): 1009-1034.